SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Trends > Health claims

NHCR article 13 health claims fallout

Valio: How a probiotic firm exists in the “red ocean” of EU health claims

1 commentBy Shane Starling , 14-Jan-2013
Last updated on 14-Jan-2013 at 18:04 GMT2013-01-14T18:04:04Z

Crittenden:

Crittenden: "...we are endeavoring to focus our clinical nutrition research in areas that would provide a competitive edge over the large ‘red ocean’ created by the 13.1 list.”

Finnish dairy and probiotics firm Valio says EU health claim laws are forcing it to add approved vitamins and minerals to products like probiotics that have failed to win EU health claims.

Valio VP in R&D Ross Crittenden said the European Union nutrition and health claim regulation (NHCR) had created a “red ocean” of rejected claims of 1000s of claims that included about 300 rejections for various probiotic strains including Valio’s.

“The generic list of allowable claims for simple ingredients, such as vitamins and minerals, is so extensive that it is now possible to formulate and promote products with any myriad of health claims,” Crittenden said ahead of presentations the chair of the Global Alliance for Probiotics (GAP) will give at upcoming Probiotech and Microbiota conference in Brussels on February 5-6.

Crittenden raised the oft-spoken crimping of innovation as another side-effect of the NHCR’s article 13 list of approved and rejected claims.

“As an example, using the natural components present in milk it is possible to apply up to 10 health claims. This means that it is very difficult to justify the risk and expense of developing a new ingredient, for which the health claim may not be sufficiently differentiated in consumers’ minds from those which can be applied by incorporating ingredients on the 13.1 list.”

“Red ocean”

He added: “The failure to gain probiotic claims thus far and the ratification of the 13.1 list is a double blow for the development of new probiotic ingredients.”

“Food manufacturers are already re-formulating products to maintain current consumer health messages and questioning investments in new clinical research to support currently unapproved health claim ingredients.”

“At Valio, we are endeavoring to focus our clinical nutrition research in areas that would provide a competitive edge over the large ‘red ocean’ created by the 13.1 list.”

Guidance

Crittenden, speaking as GAP chair, said probiotics had been rejected under the NHCR despite the fact the European Union itself had spent around €70m on research associated with the strains.

“One of the reasons that applications for probiotic claims have not been accepted by EFSA is that the first guidance note on gut and immunity claims were only provided in April 2011, more than two years after the deadline for submission of Article 13.1 claims-dossiers.”

“The current guidance, being by necessity generic, also leaves many open questions in the design of probiotic clinical trials and the preparation of claims dossiers in this new and relatively complex field of science.” 

“The absence of a mechanism by which applicants can get adequate feedback prior to embarking on expensive human trials or submitting dossiers is, in many cases, paralyzing companies’ confidence in investing in new science.”

Probiotech and Microbiota 2013

Probiotech and Microbiota 2013 joins two conferences to join the dots between the lab and leading edge pre- and probiotic products in food, supplements and cosmetics.

Find out more here .

1 comment (Comments are now closed)

EFSA not fit for purpose

Another example of the crippling ineptitude of the Eurocrats and their quasi-scientific flunkies in EFSA. Their 'consumerist' position is actively harming public health; by preventing good science from arriving in the market place they are contributing to the untimely deaths of many EU citizens.

Report abuse

Posted by paul clayton
14 January 2013 | 15h032013-01-14T15:03:14Z

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars